MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. The company serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, the company is based in Sophia-Antipolis, France, and has a US subsidiary in Boston.
MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
MEDIAN Technologies has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging
and quality execution for better screening, diagnosis, and monitoring of patients.”